X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

DMAC

Closed

Diamedica Therapeutics Inc

3.57
-0.33 (-8.46%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.9
Day's Range: 3.515 - 3.98
Send
When Written:
 
1.53
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing novel treatments for neurological and kidney diseases. The company is based in Minneapolis, Minnesota, and was founded in 2000.

DiaMedica's lead product candidate is DM199, a recombinant human tissue kallikrein-1 protein that is being developed for the treatment of acute ischemic stroke and chronic kidney disease. DM199 has shown promising results in preclinical studies and early-stage clinical trials.

The company is also exploring the potential of DM199 in other indications, including diabetic kidney disease and traumatic brain injury. Additionally, DiaMedica is developing a second product candidate, DM204, for the treatment of cognitive impairment associated with Alzheimer's disease and other neurological disorders.

DiaMedica has partnerships with several academic institutions and research organizations, including the National Institutes of Health and the Mayo Clinic. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "DMAC."

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X